Vanguard 7
Vanguard 7
Not authorised
- Canine parainfluenza virus, strain NL-CPI-5, Live
- Canine adenovirus 2, strain Manhattan, Live
- Canine distemper virus, strain Snyder Hill, Live
- Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
- Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
- Canine parvovirus, strain NL-35-D, Live
Product identification
Medicine name:
Vanguard 7
Active substance:
- Canine parainfluenza virus, strain NL-CPI-5, Live
- Canine adenovirus 2, strain Manhattan, Live
- Canine distemper virus, strain Snyder Hill, Live
- Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
- Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
- Canine parvovirus, strain NL-35-D, Live
Target species:
-
Dog
Route of administration:
-
Subcutaneous use
Product details
Active substance and strength:
-
Canine parainfluenza virus, strain NL-CPI-5, Live1000000.00/50% tissue culture infectious dose1.00Dose
-
Canine adenovirus 2, strain Manhattan, Live1585.00/50% tissue culture infectious dose1.00Dose
-
Canine distemper virus, strain Snyder Hill, Live1000.00/50% tissue culture infectious dose1.00Dose
-
Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated40.00/Hamster protective Dose 80%1.00millilitre(s)
-
Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated40.00/Hamster protective Dose 80%1.00millilitre(s)
-
Canine parvovirus, strain NL-35-D, Live10000000.00/50% tissue culture infectious dose1.00millilitre(s)
Pharmaceutical form:
-
Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
-
Subcutaneous use
-
Dog
-
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QI07AI02
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Surrendered
Authorised in:
-
Germany
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)
Marketing authorisation holder:
- Zoetis Deutschland GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
- Zoetis Belgium
Responsible authority:
- Paul-Ehrlich-Institut
Authorisation number:
- 8a/91
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Summary of Product Characteristics
English (PDF)
Download Published on: 12/01/2023
German (PDF)
Published on: 12/01/2023
How useful was this page?:
